Table 1.

Severity of neurocognitive TEAEs

	Placebo-controlled pool		Ezetimibe-controlled pool		Pool of all studies
	Alirocumab (n = 2476)	Placebo (n = 1276)	Alirocumab (n = 864)	Ezetimibe (n = 618)	Alirocumab (n = 3340)	Control (n = 1894)
Any neurocognitive TEAE, n (%)	22 (0.9)	9 (0.7)	10 (1.2)	8 (0.9)	32 (1.0)	17 (0.9)
Mild	14 (63.6)	4 (44.4)	9 (90.0)	4 (50.0)	23 (0.7)	8 (0.4)
Moderate	8 (36.4)	4 (44.4)	1 (10.0)	4 (50.0)	9 (0.3)	8 (0.4)
Severe	0	1 (11.1)	0	0	0	1 (0.1)

Neurocognitive TEAEs categorized using the Sponsor CMQ.

CMQs, custom Medical Dictionary of Regulatory Activities queries; TEAEs, treatment-emergent adverse events.